Arcutis Biotherapeutics (NASDAQ: ARQT): Time to Have Skin in This Game!

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage company creating a portfolio of targeted therapies to treat immune-mediated dermatological diseases and conditions. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Market Cap: $2.47B; Current Share Price: 20.57 USD Data by YCharts ZORYVE® - Time to Have Skin in This Game! The Company has...

08 October, 2025 0 Comments

KemPharm – Collaboration and License Agreement for KP415 and KP484, its ADHD Candidates, May Help Reinvigorate the Company

KemPharm (NASDAQ: KMPH), a specialty pharmaceutical company, has entered into a collaboration and licensing agreement with an affiliate of Gurnet Point Capital (GPC) in exchange for an upfront payment of $10 million, in addition to receiving pre-approval cost reimbursements, regulatory milestone and sales milestone amounting...

09 September, 2019 0 Comments

WordPress Video Lightbox Plugin

Popular Stories

- Arcutis Biotherapeutics (N

- Nexgel: Bringing Innovatio

- Ekso Bionics: Advancing Ra

- Esperion: Revolutionizing

- AMSC: Restructuring the Po

- Harrow Inc: Envisioning a

SAMPLE REPORTS

License Agreement Tag

KemPharm – Collaboration and License Agreement for KP415 and KP484, its ADHD Candidates, May Help Reinvigorate the Company

Quick Links

Our Service Location

Submit a Request